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Abstract
Background: Idiopathic pulmonary hemosiderosis (IPH) is a rare disorder of unknown etiology characterized by
chronic pulmonary hemorrhage and presents with a triad of anemia, hemoptysis and pulmonary infiltrates. IPH is a
diagnosis of exclusion with a variable and disparate clinical course. Despite existing therapies, few children achieve
full remission while others have recurrent hemorrhage, progressive lung damage, and premature death.
Methods: We surveyed physicians who care for patients with IPH via a web-based survey to assess the most
common practices. 88 providers responded, caring for 274 IPH patients from five continents.
Results: 63.3 % of respondents had patients that were initially misdiagnosed with anemia (60.0 %) or gastrointestinal
bleed (18.2 %). Respondents varied in diagnostic tools used for evaluation. The key difference was in the use of lung
biopsy (51.9 %) for diagnosis. Common medications respondents used for treatment at initial presentation and chronic
maintenance therapy were corticosteroids (98.7 and 84.0 %, initial and chronic therapy respectively), hydroxychloroquine
(33.3 and 64.0 %), azathioprine (8.0 and 37.3 %), and cyclophosphamide (4.0 and 16.0 %). There was agreement on the
use of corticosteroids for exacerbation amongst all respondents. Reported deaths before adulthood occurred in 7.3 %
of patients. We conclude that there were common features and specific variations in physician management of IPH.
Respondents were divided on whether to perform lung biopsy for diagnosis.
Conclusion: Despite the availability of various immunomodulators, corticosteroids remained the primary therapy. We
speculate that the standardization of care for diffuse alveolar hemorrhage will improve patient outcomes.
Keywords: Interstitial lung disease, Lung pathology, Pulmonary vascular disorders, Vasculitis, Idiopathic pulmonary
hemosiderosis, Diffuse alveolar hemorrhage, Capilliritis, Lung biopsy
Background
Idiopathic pulmonary hemosiderosis (IPH) is a rare dis-
order characterized by diffuse alveolar hemorrhage. Its
incidence is about 0.5–1 case per million [1, 2]. IPH
classically presents with a triad of anemia, hemoptysis
and diffuse pulmonary infiltrates. Some patients achieve
full remission while others have recurrent hemorrhage,
progressive lung damage and premature death [3]. IPH
is more common in children than adults with patients
often presenting prior to 10 years of age. However, the
diagnosis can be delayed in young children who swallow
their sputum and do not present with hemoptysis [3–7].
IPH is a diagnosis of exclusion and other etiologies such
as autoimmune, cardiac, and infectious disease must be
assessed first. Basic diagnostic studies can include
hemoglobin content, reticulocyte count, chest radiog-
raphy, bronchoalveolar lavage, chest CT, and lung biopsy.
Evaluation for milk protein allergy (Heiner Syndrome) and
celiac disease (Lane Hamilton Syndrome) can also be part
of the diagnostic evaluation [8–13].
Though there is a consensus on the evaluation of child-
hood interstitial lung disease in children less than 2 years
of age, there is no consensus on how to evaluate diffuse
alveolar hemorrhage or utilize available therapies [14].
Treatment with corticosteroids is the most common ap-
proach, but other treatments, such as hydroxychloroquine
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(HCQ), azathioprine (AZA) and cyclophosphamide (CYC)
have been proposed in small pediatric case studies and
adult trials [3, 6, 7, 15–22]. Rare treatment options like
intravenous immunoglobulin (IVIG), plasmapharesis,
methotrexate (MTX), N-acetylcysteine, mycophenolate, 6-
mercaptopurine and diet modification have also been sug-
gested in case reports [3, 7, 10, 11, 19, 20, 22–25]. Given
the wide variety of diagnostic and treatment modalities for
IPH, we surveyed providers to elicit commonalities in
management and determine IPH morbidity and mortality.
Methods
Pediatricians and pediatric subspecialists were surveyed
internationally using pediatric pulmonology and rheuma-
tology subspecialty list serves. The web-based survey con-
tained 27 questions. Providers were asked about their
practice setting and personal practices for their patients
with IPH. Specific questions included details of which
diagnostic modalities and medications they used for acute
and chronic management of alveolar hemorrhage for each
of their patients. Lastly, respondents were given the op-
portunity to write in comments not addressed in the
survey. Morbidity was assessed by time to diagnosis, mis-
diagnoses and hospitalization rate per patient. Mortality
was calculated based on the number of patient deaths be-
fore the age of 21 years. We used standard descriptive sta-
tistics to describe our results such as percentages, means
with standard deviations for parametric data, and medians
with interquartile ranges (IQR) for non-parametric data.
Percentages were calculated based on the total number of
responses per question.
Results
Eighty-eight providers responded to the survey, represent-
ing 274 IPH patients. Respondents saw 0–20 patients per
physician in their clinic (median = 3, IQR 1 to 4). Most re-
spondents were pediatric pulmonologists (n = 73, 83.0 %).
Respondents were in practice for 1 to 51 years (median =
13, IQR 3 to 26). Most respondents practiced in an aca-
demic (n = 80, 94.1 %) and urban setting (n = 74, 85.1 %).
Respondents were from five continents representing 15
countries, most being from the United States (n = 63,
72.4 %) (Table 1).
Most patients were diagnosed more than 2 months after
presentation (n = 112, 47.7 %) with 14.5 % (n = 34) of
patients taking longer than 6 months to diagnosis. Most
respondents (n = 50, 63.3 %) reported that their patients
were initially misdiagnosed.
Misdiagnoses included anemia (n = 33, 60.0 %), gastro-
intestinal bleeding (n = 10, 18.2 %), pneumonia (n = 6,
10.9 %), and asthma (n = 3, 5.5 %). Other misdiagnoses
included tachypnea/hemoptysis, pulmonary infarct and
upper respiratory tract infection reported by one phys-
ician each.
Since IPH is a diagnosis of exclusion, providers
assessed for rheumatologic disease (n = 83, 97.6 %),
other pulmonary disease (n = 75, 88.2 %), cardiac disease
(n = 71, 83.5 %), infection (n = 69, 81.2 %), milk protein al-
lergy (n = 54, 63.5 %), and celiac disease (n = 31, 36.5 %).
Milk protein allergy (n = 35, 12.8 %), trisomy 21 (n = 18,
6.6 %), and celiac disease (n = 13, 4.7 %) were comorbidi-
ties reported. Written responses for comorbidities by four
or less respondents included mild P-ANCA positivity,
lupus, hereditary spherocytosis, chronic granulomatous
disease, pulmonary arteriovenous malformation, foreign
body, asthma, tree nut allergy, autoimmune hepatitis, de-
velopmental delay, prematurity, small stature, and meta-
bolic disorder.
Diagnostic methods used by providers included bron-
choalveolar lavage (n = 72, 91.1 %), chest CT (n = 60,
75.9 %), chest radiography (n = 54, 68.4 %), hemoglobin
and reticulocyte count (n = 55, 69.6 %), and lung biopsy
(n = 41, 51.9 %). Twenty-four combinations of these
diagnostic methods were reported. The most common
70.9 % of responses are described in Table 2. The two
most frequent combinations included bronchoalveolar
lavage, chest CT, chest radiography, and hemoglobin
and reticulocyte count (n = 37, 46.9 %). Of that, respon-
dents differed in the utilization of lung biopsy (lung bi-
opsy: n = 21, 56.8 % versus without lung biopsy: n = 16,
43.2 %).
Respondents were asked about which medications
were used for initial presentation, maintenance, and ex-
acerbation of IPH (Table 3). On initial presentation,
most respondents used corticosteroids (n = 74, 98.7 %)
and 61.3 % (n = 46) of those respondents used corticoste-
roids alone. In addition to corticosteroids, HCQ (n = 25,
33.3 %), AZA (n = 6, 8.0 %), and CYC (n = 3, 4.0 %) were
used for initial presentation. The most common medica-
tions respondents used for maintenance therapy were
corticosteroids (n = 63, 84.0 %), HCQ (n = 48, 64.0 %),
Table 1 Physician respondent characteristics
Characteristics n (%)
Specialty, n = 88
Pediatric pulmonologist 73 (83)
Pediatric rheumatologist 13 (14.8)
Pediatrician 1 (1.1)
Allergist 1 (1.1)
Practice location, n = 87
North America 69 (79.3)
Middle East 6 (6.9)
Europe 5 (5.7)
South America 3 (3.4)
Asia 2 (2.3)
Africa 2 (2.3)
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AZA (n = 28, 37.3 %), and CYC (n = 12, 16.0 %). For IPH
exacerbation, all respondents agreed on the use of cortico-
steroids (n = 72, 100.0 %).
Steroid dosage and frequency for an IPH exacerbation
was queried as a free text response. Of the 59 respondents,
69.5 % (n = 41) used 0.5–8 mg/kg/day of prednisone, pred-
nisolone, or methylprednisolone for 1–4 weeks followed
by a taper, while 30.5 % (n = 18) used methylprednisolone
10–30 mg/kg/dose given for 1–3 consecutive days at
weekly or monthly intervals.
Most patients were either not readmitted over the
course of a year (n = 69, 30.4 %) or had 1–2 admissions
per year (n = 121, 53.3 %) for an IPH exacerbation. Thirty-
seven (16.3 %) patients had more than three admissions
per year for alveolar hemorrhage. Of the 67 physicians
who responded to the question, representing 247 patients,
18 (7.3 %) patients died before 21 years of age.
Discussion
Though IPH is a rare disorder, we were able to obtain
responses from providers internationally caring for 274
patients, one of the largest IPH cohorts to date. We
found a mortality of 7.3 %, which is lower than the 16
to 60 % mortality previously reported [3, 6, 7, 25–27].
Physician responses highlighted the commonalities and
differences in the management of IPH.
For diagnosis, respondents agreed on the exclusion of
rheumatologic disease and obtaining a bronchoalveolar
lavage, chest CT, chest radiography, hemoglobin and
reticulocyte count. Respondents were divided on
whether to perform lung biopsy which can assess for
other etiologies of diffuse alveolar hemorrhage like
capillaritis. Identifying capillaritis is important because
it requires an aggressive treatment regimen early on to
avoid serious outcomes [25].
We speculate that respondents who did not pursue
lung biopsy relied on autoimmune serology results to
exclude capillaritis and diagnose IPH. Case series on
diffuse alveolar hemorrhage showed that some patients
had negative autoimmune serologies at initial presenta-
tion that later became positive; this indicates that
serologies at diagnosis are insufficient to diagnose
capillaritis versus IPH [4, 7, 28–31]. This is reinforced
by Fan and colleagues who found that more than a
third of their diffuse alveolar hemorrhage patients had
negative autoimmune serologies, but had positive lung
biopsies for capillaritis [26, 32]. These studies suggest
that lung biopsy is essential to exclude capillaritis in
the absence of positive autoimmune serologies and to
exclude other disease processes such as infection or
other forms of interstitial lung disease requiring differ-
ent interventions [14].
Respondents agreed on the use of corticosteroids for
treatment at initial presentation and for exacerbations.
The responses are consistent with Godfrey’s review of 83
published IPH cases, where 92.0 % of patients received
corticosteroids for initial treatment with 61.0 % of those
patients having no other therapies recorded at initiation.
The steroid regimens included methylprednisolone
2–4 mg/kg/day or 30 mg/kg/dose monthly followed by
a steroid wean to a dose as low as prednisolone 0.5–1 mg/
kg every other day [27]. For exacerbation, the use of inter-
mittent methylprednisolone as a means to decrease the
side effects of daily corticosteroids and IVIG are common
amongst our respondents; however, the data for both regi-
mens in patients with alveolar hemorrhage is scant. Most
studies are in patients with other rheumatologic disorders
and immune mediated renal abnormalities [25, 33–38].
We found that corticosteroids in combination with
HCQ, AZA, or CYC were the most common regimens
for maintenance therapy amongst our respondents. In
2004, European Respiratory Society Task Force found
Table 2 Evaluations performed to diagnose IPH†
BAL Chest CT CXR H&R Biopsy Other n (%)
+ + + + + + a 21 (26.6)
+ + + + + b 16 (20.3)
+ + + 5 (6.3)
+ + + + 5 (6.3)
+ + + 5 (6.3)
+ 4 (5.1)
aother included echocardiogram, IgE, PFTs, and/or negative autoimmune labs
bother included transfer factor, and/or negative autoimmune labs
†Responses less than 5 % are not shown
Table 3 Treatment medications used for initial presentation,
maintenance and exacerbations†
Initial Presentation
Steroids HCQ CYC AZA IVIG n (%)
+ 46 (61.3)
+ + 15 (20)
+ + + 4 (5.3)
Maintenance
Steroids HCQ CYC AZA IVIG n (%)
+ + 27 (36.0)
+ 9 (12.0)
+ + + 7 (9.3)
+ + 6 (8.0)
+ 4 (5.3)
+ + + + 4 (5.3)
Exacerbations
Steroids HCQ CYC AZA IVIG n (%)
+ 55 (76.4)
+ + 17 (23.6)
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that corticosteroids (80.2 %, prednisolone 1–2 mg/kg/
day) and HCQ (32.8 %, 6–10 mg/kg/day dosed twice
daily) were the regimens most used for both pediatric and
adult interstitial lung disease. 73.9 % of the ERS respon-
dents reported a good to partial response to corticoste-
roids and HCQ. Pulmonary hemosiderosis was the fourth
most common diagnosis in their patient population [39].
CYC and AZA were also used by our respondents.
CYC was demonstrated to be lifesaving for adults with
vasculitis and alveolar hemorrhage in the 1970’s despite
toxicities such as hemorrhagic cystitis, infertility, malig-
nancy and pulmonary fibrosis [40]. Due to the toxicity
profile for CYC, alternative maintenance therapies with
better side effect profiles are currently under investiga-
tion. A favorable response was noted in adult clinical
drug trials such as CYCAZAREM. The CYCAZAREM
study conducted by the European Vasculitis Study
Group described the utility of AZA for maintenance
medication after induction with CYC. Additional trials
like the REMAIN drug trial looking at low dose cortico-
steroids versus AZA will be of particular interest for
pediatric physicians heavily dependent on corticosteroids
[3, 20, 22, 25, 39–41]. 6-mercaptopurine (6MP) is a thio-
purine like AZA with AZA being a prodrug of 6MP
[42]; although none of the providers in our survey re-
ported using six mercaptopurine, it has been used as an
IPH maintenance therapy by Luo et al. [24]. It is unclear
if CYC or AZA/6MP is as effective in children. Further-
more, side effects of each therapy may vary in different
patients, which is important in determining if the patient
will tolerate the therapy long term. Clinical studies in in-
flammatory bowel disease revealed a subset of patients
have more side effects, such as leukopenia, to thiopur-
ines (AZA/6MP) thought to be due to lack of thiopurine
methyltransferase activity, an important enzyme in thio-
purine metabolism [24, 42–44]. Therefore, more re-
search needs to be done in the side effects of therapies
for patients with alveolar hemorrhage as well.
A major limitation of our survey method was recall bias.
Respondents possibly did not report all their patients, mis-
reported patient information, or provided incomplete data
sets. Thus, physician management could not be directly
correlated with patient outcomes.
Conclusion
Our study revealed commonalities and disparities in IPH
care. In practice, half of our respondents avoided the
performance of lung biopsy. Corticosteroids remained
the mainstay for treatment even in light of available im-
munomodulators. These trends point towards the need
to standardize IPH care. Establishing a diffuse alveolar
hemorrhage registry that links diagnostic and treatment
regimens to patient specific outcomes will be necessary
to improve IPH care. Improved morbidity and mortality
for this rare and grave disease may be achieved by diag-
nostic algorithms that outline the indications for a lung
biopsy and efficacy trials for steroid sparing agents.
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